{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T23:30:19Z","timestamp":1771889419591,"version":"3.50.1"},"reference-count":10,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,12,22]],"date-time":"2008-12-22T00:00:00Z","timestamp":1229904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This subgroup analysis evaluated the effect of once\u2010daily oral deferasirox on labile plasma iron (LPI) levels in patients from the prospective, 1\u2010yr, multicentre ESCALATOR study. Mean baseline liver iron concentration and median serum ferritin levels were 28.6\u2003\u00b1\u200310.3\u2003mg Fe\/g dry weight and 6334\u2003ng\/mL respectively, indicating high iron burden despite prior chelation therapy. Baseline LPI levels (0.98\u2003\u00b1\u20030.82\u2003\u03bcmol\/L) decreased significantly to 0.12\u2003\u00b1\u20030.16\u2003\u03bcmol\/L, 2\u2003h after first deferasirox dose (<jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.0006). Reductions from pre\u2010 to post\u2010deferasirox administration were also observed at all other time points. Compared to baseline, there was a significant reduction in preadministration LPI that reached the normal range at week 4 and throughout the remainder of the study (<jats:italic>P\u2003<\/jats:italic>\u2264<jats:italic>\u2003<\/jats:italic>0.02). Pharmacokinetic analysis demonstrated an inverse relationship between preadministration LPI levels and trough deferasirox plasma concentrations. Once\u2010daily dosing with deferasirox\u2003\u226520\u2003mg\/kg\/d provided sustained reduction in LPI levels in these heavily iron\u2010overloaded patients, suggesting 24\u2010h protection from LPI. Deferasirox may therefore reduce unregulated tissue iron loading and prevent further end\u2010organ damage.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2008.01204.x","type":"journal-article","created":{"date-parts":[[2008,12,20]],"date-time":"2008-12-20T23:11:27Z","timestamp":1229814687000},"page":"454-457","source":"Crossref","is-referenced-by-count":55,"title":["Reduction in labile plasma iron during treatment with deferasirox, a once\u2010daily oral iron chelator, in heavily iron\u2010overloaded patients with <b>\u03b2<\/b>\u2010thalassaemia"],"prefix":"10.1111","volume":"82","author":[{"given":"Shahina","family":"Daar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Pathare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanspeter","family":"Nick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Kriemler\u2010Krahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdel","family":"Hmissi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dany","family":"Habr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Taher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,21]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1978.tb03662.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-3886(00)00087-4"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2004.10.003"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb03318.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90061-7"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13309-0"},{"key":"e_1_2_5_8_2","first-page":"873","article-title":"Randomized phase II trial of deferasirox (Exjade, ICL670), a once\u2010daily, orally\u2010administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload","volume":"91","author":"Piga A","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0807"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409013310903"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.3.739"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2008.01204.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2008.01204.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T19:45:45Z","timestamp":1696967145000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2008.01204.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,21]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1111\/j.1600-0609.2008.01204.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01204.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,21]]}}}